Top

Published in:

01-05-2008 | Review Article

Guide to the Use of Proton Pump Inhibitors in Adult Patients

Authors: Vandana Boparai, Jaishree Rajagopalan, Dr George Triadafilopoulos

Published in: Drugs | Issue 7/2008

Abstract

Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they effectively alleviate acid-peptic symptoms and facilitate healing of inflamed or ulcerated mucosa. Although the use of PPIs is nowadays short term in patients with Helicobacter pylori-related peptic ulcer disease, these drugs are increasingly used long term, frequently for a lifetime, in patients with typical or atypical symptoms of gastro-oesophageal reflux disease, and in NSAID or aspirin users at risk for gastrotoxicity and related complications, such as bleeding, perforation and gastric outlet obstruction. This review outlines the essentials of PPI pharmacology, the safety and adverse profiles of the various available agents, and balances them against their clinical short- and long-term benefits. PPI use, prophylactically or with a therapeutic intent may also be combined with other strategies, such as endoscopic therapy, surgery or antibacterial use. Various clinical endpoints, such as symptom relief, mucosal healing, prevention of disease recurrence or complications, and cancer chemoprevention, are discussed and unmet needs are highlighted.

Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118(2 Suppl. 1): S9–31PubMedCrossRef

De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91(2): 333–7PubMed

Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol 2001; 13: 611–6PubMedCrossRef

Williams MP, Sercombe J, Hamilton MI, et al. A placebo controlled trial to assess the effects of 8 days of dosing with rabeprozole versus omeprazole on 24hr intragastric acidity and plasma gastric concentration in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079–89PubMedCrossRef

Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559–68PubMedCrossRef

Ip S, Bonis P, Tatsioni A, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: evidence report/technology assessment number 1. Rockville (MD): Agency for Healthcare Research and Quality, 2005 Dec

Nelson WW, Vermeulen LC, Geurkink EA, et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med 2000; 160: 2491–6PubMedCrossRef

Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955–60PubMedCrossRef

Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33–8PubMedCrossRef

10.

Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947–53PubMedCrossRef

11.

Consumer Reports®. Drugs to treat heartburn, ulcers, and stomach acid reflux: the proton pump inhibitors comparing effectiveness, safety, and price. Available from URL: http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/PPIsUpdate-FINAL.pdf [Accessed 2008 Mar 5]

12.

Allgood LD, Grender JM, Shaw MJ, et al. Comparison of Prilosec OTC (omeprazole magnesium 20.6 mg) to placebo for 14 days in the treatment of frequent heartburn. J Clin Pharm Ther 2005; 30: 105–12PubMedCrossRef

13.

Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20mg on-demand is more acceptable to patients than continuous lansoprazole 15mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study. Aliment Pharmacol Ther 2004; 20: 657–65PubMedCrossRef

14.

McQuaid KR, Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials. Clin Gastroenterol Hepatol 2005; 3: 553–63PubMedCrossRef

15.

Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1–16CrossRef

16.

Klauser AG, Schindlebeck NE, Muller-Lissner SA. Symptoms in gastroesophageal reflux disease. Lancet 1990; 335: 205–8PubMedCrossRef

17.

Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis 2000; 18: 20–6PubMedCrossRef

18.

Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs 2004; 64: 277–95PubMedCrossRef

19.

Kahrilas PJ. Refractory heartburn. Gastroenterology 2003; 124: 1941–5PubMedCrossRef

20.

Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798–810PubMedCrossRef

21.

Venebles TL, Newland RD, Patel AC, et al. Omeprazole 10mg once daily, omeprazole 20 milligrams once a daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for relief of symptoms of gastro-esophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965–73CrossRef

22.

Miner Jr P, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenter 2002; 97: 1332–9PubMedCrossRef

23.

Johnston BT, McFarland RJ, Collins JS, et al. Symptoms index as a marker of gastro-oesophageal reflux disease. Br J Surg 1992; 79: 1054–5PubMedCrossRef

24.

Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907–14PubMedCrossRef

25.

Talley NJ, Lauritsen K, Tunturi-Hihnalas H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54PubMedCrossRef

26.

Pace F, Torini M, Pallotta S, et al. Systematic review: maintenance treatment of GERD with proton pump inhibitors taken ‘on demand’. Aliment Pharmacol Ther 2007; 26: 195–204PubMedCrossRef

27.

Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut 1999; 45: 172–80PubMedCrossRef

28.

Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65PubMedCrossRef

29.

Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249–58CrossRef

30.

Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575–83PubMedCrossRef

31.

Fennerty MB, Johanson J, Hwang C, et al. Esomeprazole 40mg versus lansoprazole 30mg in healing and symptomatic relief in patients with moderate to severe erosive esophagitis (Los Angeles Grades C or D). Aliment Pharmacol Ther 2005; 21(4): 455–63PubMedCrossRef

32.

Johnson DA, Hoyle PE, Traxler BM, et al. An evidence-based approach provides a quantitative assessment of the efficacy of esomeprazole for healing of erosive esophagitis based on disease severity [abstract]. Am J Gastroenterol 2003; 98: S16

33.

Vieth M, Kulig M, Leodolter A, et al. Histological effects of esomeprazole therapy on the squamous epithelium of the distal esophagus. Alim Pharmacol Ther 2006; 23: 313–9CrossRef

34.

Pilotto A, Franceschi M, Leandro G, et al. Comparison of four proton pump inhibitors for short term treatment of esophagitis in elderly patients. World J Gastroenterol 2007 Sep 7; 13(33): 4467–72PubMed

35.

Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; (2): CD003245

36.

Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12PubMed

37.

Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27–34PubMedCrossRef

38.

Klok RM, Postma MJ, van Hout BA, et al. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 2003; 17: 1237–45PubMedCrossRef

39.

Kaspari S, Kupcinskas L, Heinze H, et al. Pantoprazole 20mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005; 17: 935–41PubMedCrossRef

40.

Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002; 37: 642–7PubMedCrossRef

41.

Sjostedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005; 22: 183–91PubMedCrossRef

42.

Dean BB, Gano Jr AD, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656–64PubMedCrossRef

43.

Bate CM, Griffin SM, Keeling PW, et al. Reflux symptom relief with omeprazole in patients without unequivocal esophagitis. Aliment Pharmacol Ther 1996; 10: 547–55PubMedCrossRef

44.

Richter JE, Kovacs TOG, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 1996; 13: 795–804CrossRef

45.

Chey W, Huang B, Jackson R. Lansoprazole and esomeprazole in symptomatic GERD, a double blind, randomised, multicenter trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003; 23(2): 69–84CrossRef

46.

Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. Gut 1999; 45: 1131–6CrossRef

47.

Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms a double blind randomized trial. Clin Gastroenterol Hepatol 2006; 4: 50–6PubMedCrossRef

48.

Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974–9PubMedCrossRef

49.

Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 1810–6PubMedCrossRef

50.

Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51: 885–92PubMedCrossRef

51.

Richter JE, Zuccaro G. Esophageal diseases. In: Classen M, Tytgat GNJ, Lightdale CJ, editors. Gastroenterological Endoscopy. Stuttgart: Thieme Publishers, 2002: 452–65

52.

Shaker R, Castell DO, Schoenfeld PS, et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487–93PubMedCrossRef

53.

Fass R, Traxler BM, Thomas S, et al. Once daily esomeprazole and twice daily lansoprazole for nocturnal heartburn in patients with GERD [abstract]. Am J Gastroenterol 2003; 98: S36

54.

Castell DO. Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother 2005; 6: 2501–10PubMedCrossRef

55.

Castell D, Bagin R, Goldlust B, et al. Comparison of the effects of immediate release omeprazole powder for oral suspension and pantoprazole delayed release tablets on nocturnal acid breakthrough in patients with symptomatic gastroesophageal reflux. Aliment Pharmacol Ther 2005; 21: 1467–74PubMedCrossRef

56.

Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907–15PubMed

57.

Swarbrick ET, Gough AL, Foster CS, et al. Prevention of recurrence of oesophageal stricture: a comparison of lansoprazole and high-dose ranitidine. Eur J Gastroenterol Hepatol 1996; 8: 431–8PubMed

58.

Triadafilopoulos G. Acid and bile reflux in Barrett’s esophagus: a tale of two evils. Gastroenterology 2001; 121: 1502–6PubMedCrossRef

59.

Triadafilopoulos G. Management of Barrett’s esophagus with and without dysplasia. Scand J Gastroenterol Suppl 2003; 237: 40–6PubMedCrossRef

60.

Fitzgerald RC, Lascar R, Triadafilopoulos G. Barrett’s oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001; 15: 269–76PubMedCrossRef

61.

El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol 2004; 99: 1877–83PubMedCrossRef

62.

Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barret’s esophagus. Med J Aust 2004; 180: 387–91PubMed

63.

Yeh RW, Triadafilopoulos G. Endoscopic therapy for Barrett’s esophagus. Gastrointest Endosc Clin N Am 2005; 15: 377–97PubMedCrossRef

64.

Yeh RW, Triadafilopoulos G. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus. Dis Esophagus 2003; 16: 193–8PubMedCrossRef

65.

Hewson EG, Sinclair JW, Dalton CB, et al. Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating non-cardiac chest pain. Am J Med 1991; 90: 576–83PubMed

66.

Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry in patients with ‘reflux laryngitis’. Gastroenterology 1991; 100: 305–10PubMed

67.

Shaker R, Milbrath M, Ren J, et al. Esophago-pharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 1995; 109: 1575–82PubMedCrossRef

68.

Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Med 1994; 96: 321–6PubMedCrossRef

69.

Vaezi M, Richter J, Stasney R, et al. A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngo-pharyngeal reflux. Laryngoscope 2006; 116: 254–60PubMedCrossRef

70.

Howden CW, Leontiadis GI, Sharma VK. Randomized controlled trials comparing PPI with placebo in reflux laryngitis: a systematic review [abstract]. Gastroenterology 2004; 126: A99CrossRef

71.

Richter JE. Ear, nose and throat and respiratory manifestation of gastro-esophageal reflux disease: an increasing conundrum. Eur J Gastroenterology Hepatology 2004; 16: 837–45CrossRef

72.

Kushner JP, Steward DL. Effect of pantoprazole on typical and atypical reflux symptoms in a prospective cohort of patients with obstructive sleep disordered breathing [abstract]. Am J Gastroenterol 2004; 99: S7CrossRef

73.

Schoeffel L, Naumburger A, Gillessen A, et al. Superiority of pantoprazole 40mg versus omeprazole 20mg in relieving GERD-associated sleep disturbances [abstract]. Am J Gastroenterol 2004; 99: S237

74.

Contini S, Scarpignato C. Endoscopie treatment of gastro-oesophageal reflux disease (GORD): a systematic review. Dig Liver Dis 2003; 35: 818–38PubMedCrossRef

75.

Lundell L, Mietinnen P, Myrvold HE, et al. Continued (5-year) follow-up of a randomized clinical study comparing antireflux surgery and omeprazole in gastro-esophageal reflux disease. J Am Coll Surg 2001; 192: 172–9PubMedCrossRef

76.

Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastro-esophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331–8PubMedCrossRef

77.

Richards WO, Houston HL, Torquati A, et al. Paradigm shift in the management of gastro-esophageal reflux disease. Ann Surg 2003; 237: 638–47PubMed

78.

Chadalavada R, Lin E, Swafford V, et al. Comparative results of endoluminal gastroplasty and laparoscopic antireflux surgery for the treatment of GERD. Surg Endosc 2004; 18: 261–5PubMedCrossRef

79.

Holt S, Howden CW. Omeprazole. overview and opinion. Dig Dis Sci 1991; 36: 385–93

80.

Poynard T, Lemaire M, Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 661–5PubMed

81.

Dekkers CP, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20mg versus omeprazole 20mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179–86PubMedCrossRef

82.

Bader JP, Delchier JC. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994; 8 Suppl. 1: 47–52

83.

Lin HJ, Lo WC, Cheng YC, et al. Effects of 3 day IV pantoprazole vs omeprazole on 24hr intragastric acidity at 3 days in Chinese patients with duodenal ulcer: a single center prospective randomized, comparative, pilot trial. Clin Ther 2006; 9: 1303–7CrossRef

84.

Peura DA. Prevention of non-steroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117 Suppl. 5A: 63–71S

85.

Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037–46

86.

Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719–26

87.

Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727–34

88.

Bianchi Porro G, Lazzaroni M, Manzionna G, et al. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 1998 Apr; 12(4): 355–60PubMedCrossRef

89.

Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321(7270): 1183–7PubMedCrossRef

90.

Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238–44PubMedCrossRef

91.

Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967–73PubMedCrossRef

92.

Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033–8PubMedCrossRef

93.

Goldstein JL, Miner Jr PD, Schlesinger PK, et al. Intra-gastric acid control in nonsteroidal antiinflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006; 23: 1189–26PubMedCrossRef

94.

Hawkey C, Talley NJ, Yeomans ND, et al. Improvement with esomeprazole in patients with upper gstrointestinal symptoms taking NSAIDS including selective cox-2 inhibitors. Am J Gastroenterol 2005; 100: 1028–36PubMedCrossRef

95.

Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59: 1210–7PubMedCrossRef

96.

Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 1998; 12: 135–40PubMedCrossRef

97.

Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multi-centre study. Scand J Gastroenterol 1996; 31: 753–8PubMedCrossRef

98.

Scheinman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NS AIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701–10CrossRef

99.

Graham DY, Agrawal NM, Campbell DR, et al., for the NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double-blind, randomized, multi-center, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169–75PubMedCrossRef

100.

Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100: 2650–7PubMedCrossRef

101.

Kositchaiwat C, Ovartlarnporn B, Kachintorn U, et al. Low and high doses of rabeprazole vs omeprazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 18: 1017–21PubMedCrossRef

102.

Bazzoli F, Bianchi Porro G, et al. Treatment of Helicobacter pylori infection: indications and regimens: an update. Dig Liver Dis 2002; 34: 70–83PubMedCrossRef

103.

Hsu PI, Laik H, Lin CK, et al. Prospective randomised trial of esomeprazole vs pantoprazole based triple therapy for H. pylori eradication. Am J of Gastroenterol 2005; 100: 2387–92CrossRef

104.

Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238–46PubMedCrossRef

105.

Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996; 38: 316–2PubMedCrossRef

106.

Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123: 1006–12PubMedCrossRef

107.

Kupfer Y, Cappell MS, Tessler S. Acute gastrointestinal bleeding in the intensive care unit: the intensivist’s perspective. Gastroenterol Clin North Am 2000; 29: 275–307PubMedCrossRef

108.

Cook DJ, Guyatt GH, Salena BJ, et al. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 1992; 102: 139–48PubMed

109.

Savides TJ, Jensen DM. Therapeutic endoscopy for nonvariceal gastrointestinal bleeding. Gastroenterol Clin North Am 2000; 29: 465–87PubMedCrossRef

110.

Yilmaz S, Bayun K, Dursun M, et al. Does adding misoprostol to standard IV PPI protocol improve the outcome of aspirin/ NSAID-induced upper GI bleeding? A randomised prospective study. Dig Dis Sci 2007; 52: 110–8PubMedCrossRef

111.

Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38–43PubMed

112.

Berstad A, Holm HA, Kittang E. Experience with antipeptic agents. Scand J Gastroenterol (Suppl) 1979; 55: 121–3

113.

Berstad A. Antacids, pepsin inhibitors, and gastric cooling in the management of massive upper gastrointestinal haemorrhage. Scand J Gastroenterol (Suppl) 1987; 137: 33–8CrossRef

114.

Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 2005; 330: 568PubMedCrossRef

115.

Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. J Surg 2007; 77: 677–81

116.

Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007: 356:1631–40PubMedCrossRef

117.

Lau JY, Sung JJ, Lee KKC, et al. Effect of IV omeprazole on recurrent bleeding after endoscopie treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310–6PubMedCrossRef

118.

Bajaj JS, Dra KS, Hanson K, et al. Prospective randomized trial comparing effect of oral versus intravenous pantoprazole on re-bleeding after non-variceal upper gastrointestinal study a pilot study. Dig Dis Sci 2007; 52: 2190–4PubMedCrossRef

119.

Jensen DM. Spots and clots: leave them or treat them? Why and how to treat. Can J Gastroenterol 1999; 13: 413–5PubMed

120.

Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17: 211–6PubMedCrossRef

121.

Leontiadis G, McIntyre L, Sharma V, et al. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004; (3): CD002094

122.

Wolfe MM, Jensen RT. Zollinger-Ellison syndrome: current concepts in diagnosis and management. N Engl J Med 1987; 317: 1200–9PubMedCrossRef

123.

Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498–508PubMed

124.

Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia: best evidence synthesis. Scand J Gastroenterol (Suppl) 1995; 210: 48–52CrossRef

125.

Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377–81PubMedCrossRef

126.

Ben-Menachem T, Fogel R, Patel RV, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. Ann Intern Med 1994; 121: 568–75PubMed

127.

Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987; 106: 562–7PubMed

128.

Maton PN. Prevention of stress-related mucosal bleeding with proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 Suppl. 3: 45–52CrossRef

129.

Kantorova I, Svoboda P, Scheer P, et al Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepato-gastroenterology 2004; 51(57): 757–61PubMed

130.

Levy MJ, Seelig CB, Robinson NJ, et al. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997; 42: 1255–9PubMedCrossRef

131.

Phillips JO, Metzler MH, Palmieri MT, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24: 1793–800PubMedCrossRef

132.

Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically-significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998; 44: 527–33PubMedCrossRef

133.

Schupp KN, Schrand LM, Mutnick AH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother 2003; 37: 631–5PubMedCrossRef

134.

Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45 Suppl. 2: II37–43PubMedCrossRef

135.

Talley NJ, Zinmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259–68PubMed

136.

Karamanolis G, Caenepeel P, Arts J, et al. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006; 130: 296–303PubMedCrossRef

137.

Thomson A, Barkun A, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric treatment-prompt endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481–91PubMedCrossRef

138.

Sreedharan A, Clough M, Hemingbrough E, et al. Cost-effectiveness and long-term impact of Helicobacter pylori ‘test and treat’ service in reducing open access endoscopy referrals. Eur J Gastroenterol Hepatol 2004; 16: 981–6PubMedCrossRef

139.

Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori [abstract]. CMAJ 2000; 162 (12 Suppl.): S3PubMed

140.

Spiegel BM, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 2006; 119(448): e27–36PubMed

141.

Chey WD, Lukasik N, Huang B, et al. Lansoprazole effectively reduces the risk of GI symptom occurrence in ulcer free patients who continue chronic NSAID use [abstract]. Am J Gastroenterol 2003; 98: S296

142.

Meineche-Schmidt V. Classification of dyspepsia and response to treatment with proton-pump inhibitors. Aliment Pharmacol Ther 2004; 20: 1171–9PubMedCrossRef

143.

Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Manag 2000; 7: 29–34

144.

Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000; 14: 709–14PubMedCrossRef

145.

Katz PO, Anderson C, Khoury R, et al. Gastroesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231–4PubMedCrossRef

146.

Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9–28PubMedCrossRef

147.

Park S, Lee S, Song K, et al. The pharmacological properties of a novel acid pump antagonist, YH1885 [abstract]. Gut 2003; 52: A9

Title: Guide to the Use of Proton Pump Inhibitors in Adult Patients
Authors: Vandana Boparai
Jaishree Rajagopalan
Dr George Triadafilopoulos
Publication date: 01-05-2008
Publisher: Springer International Publishing
Published in: Drugs / Issue 7/2008
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200868070-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Guide to the Use of Proton Pump Inhibitors in Adult Patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2008

Renal Disease in Patients with HIV Infection

Drugs in the Newspapers

Management of Breakthrough Pain in Patients with Cancer

Posaconazole

Scientific Rationale for Combination of a Calcium Channel Antagonist and an HMG-CoA Reductase Inhibitor

Capecitabine, Alone and in Combination, in the Management of Patients with Colorectal Cancer